Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of acetylsalicylic acid (ASA), an irreversible inhibitor of cyclooxygenase (COX-1 and COX-2) enzymes. The enteric coating is designed to bypass initial gastric mucosal contact to reduce local irritation, though it does not eliminate systemic risk of gastric ulceration.
## Primary Indications
* Prophylaxis of myocardial infarction (MI) and ischemic stroke.
* Acute coronary syndromes (ACS).
* Secondary prevention of cardiovascular events.
* Management of stable or unstable angina.
## Adult Dosing
* **Secondary Cardiovascular Prevention:** 75 mg to 162 mg orally once daily.
* **Acute Coronary Syndrome:** Initial loading dose of 162 mg to 325 mg (non-enteric coated preferred for faster absorption if available); followed by 75 mg to 162 mg daily indefinitely.
* **Note:** Dosing varies by local protocol and clinical guidelines (e.g., AHA/ACC vs. ESC).
## Pediatric Dosing
* **Kawasaki Disease:** 80–100 mg/kg/day divided every 6 hours (acute phase) transitioning to 3–5 mg/kg/day (maintenance phase).
* **Rheumatic Fever:** 80–100 mg/kg/day divided every 4–6 hours.
* **Warning:** Aspirin is generally contraindicated in children/adolescents with viral infections due to the risk of **Reye’s Syndrome**.
## Dose Adjustments
* **Renal Impairment:** Use with caution in severe impairment; monitor for aspirin toxicity (tinnitus, metabolic acidosis).
* **Hepatic Impairment:** Avoid in severe liver disease; increased bleed risk due to impaired clotting factor synthesis.
## Contraindications
* Known hypersensitivity to salicylates or NSAIDs.
* Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
* History of asthma/nasal polyps precipitated by NSAIDs (aspirin-exacerbated respiratory disease).
* Children/teenagers with viral infections (influenza/varicella).
* Third trimester of pregnancy.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, gastric ulceration, occult blood loss.
* **Hematologic:** Increased bleeding time, thrombocytopenia.
* **Dermatologic/Hypersensitivity:** Urticaria, angioedema, bronchospasm.
* **Other:** Tinnitus (sign of salicylate toxicity).
## Key Drug Interactions
* **Antiplatelets/Anticoagulants (e.g., Clopidogrel, Warfarin, DOACs):** Synergistic effect significantly increases bleeding risk.
* **NSAIDs (e.g., Ibuprofen):** May interfere with the antiplatelet effect of low-dose aspirin; space dosing (ibuprofen 8 hours after or 30 minutes before aspirin).
* **Selective Serotonin Reuptake Inhibitors (SSRIs):** Increased risk of upper GI bleeding.
* **Alcohol:** Increases risk of gastric mucosal injury.
## Monitoring
* Monitor hemoglobin/hematocrit for signs of chronic blood loss.
* Monitor stool guaiac/occult blood periodically in high-risk patients.
* Assess renal function and electrolytes if chronic high-dose therapy is used.
* Observe for signs of salicylism (tinnitus, vertigo, confusion).
## Clinical Pearls
* **Antiplatelet effect:** Low doses (75–162 mg) are sufficient for chronic antiplatelet therapy. Higher doses (e.g., 325 mg+) do not necessarily improve cardiovascular mortality but increase GI side effects.
* **Absorption:** Enteric coating delays absorption; in the setting of an acute MI, non-enteric coated aspirin is preferred for rapid onset.
* **Surgical management:** Generally held 5–7 days prior to elective surgery depending on clinical risk and surgeon preference.
***
*Disclaimer: This information is for educational purposes only. Clinical practice guidelines and local institutional protocols should be verified before prescribing or administering medication. Always consult the latest drug monograph for comprehensive prescribing details.*
